Common Antibiotics Cut Deaths in African AIDS Patients: Study

Use of a cheap, commonly-prescribed antibiotic dramatically reduced the death toll among African patients whose immune systems had been ravaged by the AIDS virus, says a paper appearing on Monday.

The drug, co-trimoxazole, marketed as Septrim, Bactrim and other brands, is widely used to combat pneumonia and ear and urinary tract infections and has also been found to have some antimalarial properties.

Quiz on HIV / AIDS
Statistics tell us that the world HIV+ population has risen drastically from 8 million in 1990 to a whopping 33 million in 2007! Even more alarming is the fact that young people (below the age of 25) account for half of these infections! This is adequate proof for the lack of awareness among the general public even in these modern times. So take our quiz and brush up on the essential facts of HIV/AIDS.

There are 10 questions on HIV / AIDS in this quiz that will explore the depth of your knowledge and provide answers to the following:

Immune control of HIV ()
Symptoms of HIV/AIDS ()
Cure for AIDS ()
Acute HIV syndrome ()
World AIDS day ()
Western blot ()

The investigation covered 3,179 people in Uganda and Zimbabwe who were started on a course of antiretroviral therapy (ART) and whose counts of CD4 immune cells were lower than 200 cells per microlitre.

Among those given co-trimoxazole alongside the anti-HIV drugs, the risk of dying during the first three months fell by 59 percent compared to those who were not on the antibiotic.

HIV/AIDS Risk Calculator
The HIV risk quiz helps you determine risk factors for HIV.

At the 72-week stage, the reduced risk of mortality still persisted, although it evened out to 35 percent overall.

In addition, co-trimoxazole cut frequency of malaria by 26 percent.

AIDS/HIV - Distribution Pattern
Epidemiologic studies indicate three broad yet distinct geographic patterns of transmission

These benefits, together with the very low side effects, suggest doctors in Africa should also prescribe co-trimoxazole at the early stage of treatment for HIV, says the paper, published online by The Lancet.

"Co-trimoxazole prophylaxis (combined with anti-HIV treatment) is cost-effective and has a substantial public health effect," says the study.

Oral Health and AIDS - Introduction Treatment FAQs
AIDS has taken on massive proportions in modern times. It is estimated that over 15 million people are suffering from the disease and many more are harboring the dreaded Human Immunodeficiency Virus (HIV).

"Our results reinforce WHO (World Health Organisation) guidelines and provide strong motivation for provision of co-trimoxazole prophylaxis for at least 72 weeks to all adults starting combination ART in Africa."

The human immunodeficiency virus (HIV) penetrates and destroys key cells in the immune system, paving the way to AIDS, when the body becomes vulnerable to a host of opportunistic diseases.

Sub-Saharan Africa had 22.4 million people living with HIV or AIDS, amounting to two-thirds of the world total of 33.4 million, according to estimates for the end of 2008 released by the UN agency UNAIDS last November.

Source-AFP
SRM